Comparative Pharmacology
Head-to-head clinical analysis: AGGRENOX versus PLAVIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AGGRENOX versus PLAVIX.
AGGRENOX vs PLAVIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aggrenox is a combination of dipyridamole and aspirin. Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells, and erythrocytes, leading to increased extracellular adenosine which stimulates platelet adenylate cyclase, increasing cAMP levels and inhibiting platelet aggregation. Aspirin irreversibly acetylates cyclooxygenase-1 (COX-1), inhibiting thromboxane A2 synthesis, thereby reducing platelet aggregation.
Clopidogrel is a prodrug that is converted to an active metabolite by CYP450 enzymes. The active metabolite selectively inhibits the P2Y12 component of ADP receptors on the platelet surface, which prevents ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
One capsule (dipyridamole 200 mg plus aspirin 25 mg) orally twice daily.
75 mg orally once daily, with or without food. For acute coronary syndrome, a loading dose of 300 mg (or 600 mg for PCI) is given followed by 75 mg daily.
None Documented
None Documented
Aspirin: 15-20 minutes for parent drug; salicylate terminal half-life 3-6 hours (dose-dependent). Dipyridamole: terminal half-life approximately 10-12 hours. Clinical context: Typical twice-daily dosing maintains therapeutic antiplatelet effect.
Clopidogrel parent: ~6 hours; active thiol metabolite: ~30 minutes; terminal half-life of inactive metabolite(s): ~8 hours. Clinically, platelet inhibition persists for 5–7 days due to irreversible P2Y12 receptor binding.
Aspirin: renal elimination of salicylate and metabolites (primarily salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, and gentisic acid) accounts for >90% of a dose. Dipyridamole: primarily biliary excretion as glucuronide conjugates (enteric recycling); renal excretion accounts for <5% of unchanged drug.
Renal: ~50% as inactive metabolites; biliary/fecal: ~50% as inactive metabolites.
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent